spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Duchenne Muscular Dystrophy 

 HSMN NewsFeed - 28 Feb 2023
Tevard Biosciences announces collaboration with Vertex to develop novel tRNA-based therapies for Duchenne muscular dystrophy
Biopharmaceuticals
 HSMN NewsFeed - 4 Dec 2020
PTC Announces Translarna(TM) Approval in Russia for the Treatment of Duchenne Muscular Dystrophy
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 2 Jul 2020
Hansa Biopharma Announces Exclusive Agreement With Sarepta Therapeutics to Develop and Promote Imlifidase as Pre-treatment Ahead of Gene Therapy in Select Indications
Biopharmaceuticals Licensing
 HSMN NewsFeed - 17 Apr 2020
PTC Therapeutics Announces New Leadership Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Dec 2019
Cumberland Pharmaceuticals Receives FDA Approval for RediTrex(TM) Product Line
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Oct 2019
World Renowned Experts Appointed to Skyhawk Therapeutics Scientific Advisory Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Oct 2019
Avidity Biosciences Appoints Sarah Boyce as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Sep 2019
AskBio Acquires Assets from RoverMed BioSciences, Adds Nanotechnology Precision to Delivery of AAV Gene Therapeutics
Biopharmaceuticals Drug Delivery Acquisitions
 HSMN NewsFeed - 21 May 2019
Mallinckrodt Files Suit against U.S. Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) to Protect Medicaid Patient Access to Acthar(R) Gel
Biopharmaceuticals Reimbursement Litigation
 HSMN NewsFeed - 11 Dec 2018
GenEdit Closes $8.5 million Series Seed Financing
Regenerative Medicine Venture Capital Personnel
 HSMN NewsFeed - 5 Sep 2018
ARMGO Pharma Receives FDA Orphan Drug Designation for ARM210/S48168 for the Treatment of Ryanodine Receptor Type 1 Related Myopathies
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Apr 2018
Dr. Ottavio Vitolo Joins Relmada Therapeutics as Senior Vice President, Head of R&D and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Jan 2018
Skyhawk Therapeutics Launches With $8 Million in Seed Financing to Advance Its Novel Platform and Portfolio of Small Molecules That Correct RNA Expression
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 29 Nov 2017
Capricor Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for CAP-1002
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Nov 2017
United Therapeutics Announces Additional Six Months Of Regulatory Exclusivity For Adcirca(R)
Biopharmaceuticals FDA Licensing
 HSMN NewsFeed - 4 Oct 2017
Capricor Therapeutics Presents Positive Six-Month Results in Duchenne Muscular Dystrophy at World Muscle Society International Congress
Regenerative Medicine
 HSMN NewsFeed - 8 Sep 2017
Eloxx Pharmaceuticals Expands Management Team to Support Rapid Development of Lead Drug Candidate ELX-02 for the Treatment of Rare Genetic Diseases
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Jul 2017
Capricor Receives Rare Pediatric Disease Designation from FDA for CAP-1002 for Patients with Duchenne Muscular Dystrophy
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Jun 2017
PTC Therapeutics Announces Executive Promotions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 May 2017
AMO Pharma Announces FDA Fast Track Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 12 May 2017
Capricor Therapeutics Provides Update on ALLSTAR Trial
Regenerative Medicine Cardiology
 HSMN NewsFeed - 17 Feb 2017
Capricor Therapeutics Provides Update on Natriuretic Peptide Program
Biopharmaceuticals
 HSMN NewsFeed - 10 Feb 2017
FDA Approves EMFLAZA(TM) (deflazacort) Tablets and Oral Suspension for the Treatment of Duchenne Muscular Dystrophy in Patients 5 Years and Older
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Sep 2016
FDA allows Phrixus’s IND for Carmeseal-MD(TM) (P-188 NF) in Duchenne muscular dystrophy (DMD)
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Aug 2016
Mallinckrodt Receives FDA Fast-Track Designation for Synacthen(R) Depot IND Application
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Apr 2016
PhaseBio Announces Leadership Team Appointments
Biopharmaceuticals Cardiology Personnel
 HSMN NewsFeed - 23 Feb 2016
PTC Receives Refuse to File Letter from FDA for Translarna(TM) (ataluren)
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Nov 2015
Solid GT Raises $42.5 Million in Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 2 Sep 2015
Summit Therapeutics Appoints Ralf Rosskamp, MD, as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Aug 2015
WAVE Life Sciences Raises $66 Million in Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 20 Jul 2015
BioMarin Provides Program Update for Talazoparib in Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Apr 2015
PTC Therapeutics Names Eric Pauwels SVP & General Manager Commercial Operations, Americas
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Feb 2015
Catabasis Names Rick Modi Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Dec 2014
PTC Therapeutics Announces Launch of Translarna(TM) (ataluren) in Germany
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 3 Jul 2014
Akashi Therapeutics Receives Fast Track Designation for HT-100 from FDA for the Treatment of Duchenne Muscular Dystrophy
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Jul 2014
Akashi Therapeutics Receives Collective Funding of $1.5 Million to Support HT-100 Clinical Development
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 22 May 2014
Santhera Reports Positive Outcome for Catena(R)/Raxone(R) in Phase III DMD Trial Supported by Additional Respiratory Function Data
Biopharmaceuticals
 HSMN NewsFeed - 12 Dec 2013
Retrophin Announces Agreement to Acquire Kyalin Biosciences
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 14 Nov 2013
Jeffrey Paley, MD, Joins Retrophin Inc.’s Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Sep 2013
Cornelius E. Golding Joins Retrophin, Inc.’s Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Aug 2013
Retrophin Expands Management Team with Appointment of Steven R. Eby, R.Ph as Vice President, Global Strategy and Program Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Apr 2013
Retrophin Names Horacio Plotkin, M.D. as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Mar 2013
PTC Therapeutics Closes $60 Million Private Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 18 Sep 2012
Sarepta Therapeutics' Lead Therapeutic Drugs for Ebola and Marburg Viruses Receive FDA Fast Track Designation
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Jul 2012
AVI BioPharma Announces Corporate Name Change to Sarepta Therapeutics and Stock Ticker Symbol Change to "SRPT" Effective Today
Biopharmaceuticals
 HSMN NewsFeed - 30 Jan 2012
Amsterdam Molecular Therapeutics Announces European Commission Delays Decision on Glybera(R) Marketing Authorisation and Requests Further Information From the CHMP
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 9 Dec 2011
AVI BioPharma Names Jayant Aphale, Ph.D., Senior Vice President of Technical Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Aug 2011
Medistem Submits Response to FDA Clinical Hold
Regenerative Medicine FDA
 HSMN NewsFeed - 8 Jul 2011
Amsterdam Molecular Therapeutics Files Glybera(R) European Marketing Application for Re-examination
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Jun 2011
Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 Jun 2011
AVI BioPharma Names Ed Kaye, M.D., Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Jan 2011
AVI Biopharma Names Effie Toshav Senior Vice President and General Counsel
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Dec 2010
AVI BioPharma Provides Update on Duchenne Muscular Dystrophy Program
Biopharmaceuticals
 HSMN NewsFeed - 13 Dec 2010
AVI BioPharma Names Chris Garabedian Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Dec 2010
Spinal Cord Injury Patient Treated With Non-Matched Adult Stem Cells
Regenerative Medicine Neurology
 HSMN NewsFeed - 7 Dec 2010
Medistem Announces New Management Team
Regenerative Medicine Personnel
 HSMN NewsFeed - 27 Oct 2010
AVI BioPharma Announces Key Leadership Appointments to Advance Capabilities in Drug Discovery, Research and Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Sep 2010
Shire Expands Pipeline to Treat Orphan Muscle Diseases Through Collaboration With Acceleron Pharma
Biopharmaceuticals Licensing
 HSMN NewsFeed - 3 Sep 2010
Santhera and Ipsen Enter into Licensing Agreement for Fipamezole for the Treatment of Dyskinesia in Parkinson's Disease
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 21 Apr 2010
AVI BioPharma Appoints David Boyle Interim President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Apr 2010
BioMarin Launches Firdapse in the European Union
Biopharmaceuticals
 HSMN NewsFeed - 13 Apr 2010
Entest Biomedical Announces Intent to Acquire Medistem
Regenerative Medicine Mergers & Acquisitions
 HSMN NewsFeed - 25 Mar 2010
AVI BioPharma Announces Pending Changes to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Feb 2010
BioMarin to Acquire LEAD Therapeutics
Biopharmaceuticals Mergers & Acquisitions Oncology
 HSMN NewsFeed - 2 Dec 2009
AMT Announces Management Changes in Light of Refocused Strategy
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Oct 2009
AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy
Biopharmaceuticals Regulatory Neurology
 HSMN NewsFeed - 19 Feb 2009
AVI BioPharma Announces Treatment of First Patient in Systemic Clinical Trial of AVI-4658 for Treatment of Duchenne Muscular Dystrophy
Biopharmaceuticals
 HSMN NewsFeed - 12 Feb 2009
AVI BioPharma, Inc. Appoints Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Dec 2008
AVI BioPharma Files IND for Clinical Trial of Marburg Virus Treatment
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Jul 2008
AVI BioPharma Appoints New Senior Vice President and Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Jul 2008
Santhera Receives First Product Approval: Health Canada Approves Catena(R) for Treatment of Friedreich's Ataxia
Biopharmaceuticals Regulatory Neurology
 HSMN NewsFeed - 13 Mar 2008
AVI BioPharma Announces Acquisition of Ercole Biotech
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 11 Feb 2008
AVI BioPharma Names Dr. Leslie Hudson as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Nov 2007
AVI BioPharma Receives Orphan Drug Designation for AVI-4658 for Treatment of Duchenne Muscular Dystrophy
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Oct 2007
AVI BioPharma Announces Changes to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Sep 2007
Santhera Announces Start of US Phase III Clinical Trial with SNT-MC17 in Friedreich's Ataxia and Provides Details on Study Design
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 16 Aug 2007
European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 9 Jul 2007
APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease Announces Completion of Patient Enrollment
Devices Drug Delivery Interventional Cardiology
 HSMN NewsFeed - 2 May 2007
AVI BioPharma and Ercole Biotech Announce License and Drug Development Agreement for Duchenne Muscular Dystrophy and Beta Thalassemia
Biopharmaceuticals
 HSMN NewsFeed - 20 Feb 2007
Stem Cell Sciences Licenses Neural Stem Cell Technology to Merck & Co., Inc.
Biopharmaceuticals Regenerative Medicine Licensing
 HSMN NewsFeed - 3 Nov 2006
PTC Therapeutics Announces Positive Phase 2 Results For PTC124 in Cystic Fibrosis
Biopharmaceuticals
 HSMN NewsFeed - 21 Oct 2006
PTC Therapeutics Announces Encouraging Preliminary Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Biopharmaceuticals
 HSMN NewsFeed - 19 Oct 2006
FDA Awards PTC Therapeutics Orphan Products Development Grant for the Development of PTC124 in Duchenne Muscular Dystrophy
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Apr 2006
PTC Therapeutics Announces Interim Phase 2 Results of PTC124 in Cystic Fibrosis
Biopharmaceuticals
 HSMN NewsFeed - 9 Feb 2006
Successful Muscular Dystrophy Treatment Results Using AVI BioPharma Technology Published in Nature Medicine
Biopharmaceuticals
 HSMN NewsFeed - 27 Jan 2006
PTC Therapeutics Initiates Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
Biopharmaceuticals Neurology
 HSMN NewsFeed - 25 Jan 2006
CepTor Receives Dual Orphan Drug Designation for Myodur (C101) for Duchenne and Becker Muscular Dystrophies
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 17 Jan 2006
CepTor Submits Investigational New Drug Application (IND) to Initiate Clinical Trials with Myodur (C-101) in Duchenne Muscular Dystrophy (DMD) Patients
Biopharmaceuticals Neurology FDA
Return to NewsFeed  

 Additional items found! 15

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 15 additional stories matching:
Duchenne Muscular Dystrophy
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.